Cargando…

Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer

THE PURPOSE: Assessing the accuracy of multi parametric magnetic resonance (mp-MRI) after application of PI-RADS V2 for diagnosis of prostate cancer as comparison to pathological results of trans rectal ultra-sound (TRUS) guided biopsy. PATIENTS AND METHODS: 138 prostatic lesions in 23 patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Dola, Eman F., Nakhla, Osama L., Genidi, Eman A.SH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369010/
https://www.ncbi.nlm.nih.gov/pubmed/28377946
http://dx.doi.org/10.1016/j.ejro.2017.02.001
Descripción
Sumario:THE PURPOSE: Assessing the accuracy of multi parametric magnetic resonance (mp-MRI) after application of PI-RADS V2 for diagnosis of prostate cancer as comparison to pathological results of trans rectal ultra-sound (TRUS) guided biopsy. PATIENTS AND METHODS: 138 prostatic lesions in 23 patients were retrospectively assessed and analyzed with Trans rectal ultra-sound (TRUS) guided biopsy results. Those patients underwent multi parametric magnetic resonance (mp-MRI) with application of PI-RADS V2 reporting system. The sensitivity, specificity, validity, negative predictive value and positive predictive value were calculated for PI-RADS V2 reporting system compared to biopsy-proven pathological results. RESULTS: 92 out of 138 lesions were positive for Peripheral zone cancer prostate. PI-RADS V2 reporting system proved 88.04% sensitive & 93.4% specific for diagnosis of prostate cancer with negative predictive value & positive predictive value of 100%. CONCLUSION: Our results proved that mp-MRI of prostate using PI-RADS v2 scoring system had high sensitivity and specificity in diagnosis of prostate cancer and PI-RADS V2 scoring system using mp-MRI is recommended as a non-invasive diagnostic tool compared to TRUS guided biopsy.